0 Commenti
0 condivisioni
707 Views
0 Anteprima
Cerca
Scopri nuove persone e i loro amici a quattro zampe, e fai nuove amicizie
-
Effettua l'accesso per mettere mi piace, condividere e commentare!
-
Liposomes in Modern Research: From Basic Structures to Specialized Drug Delivery SystemsIntroduction The landscape of targeted drug delivery and nanomedicine has been significantly influenced by liposomes, with their application accelerating across immunotherapy, genetic medicine, and vaccine development, where they provide enhanced targeted delivery and reduced side effects. As these spherical vesicles transition from basic research to complex therapeutic applications, the...0 Commenti 0 condivisioni 1K Views 0 Anteprima
-
Allopurinol: A Cornerstone Xanthine Oxidase Inhibitor for Hyperuricemia and Gout ManagementWhat is Allopurinol? Allopurinol is a classic small-molecule purine analogue that has long been widely used for the intervention of hyperuricemia and gout-related diseases. Its core mechanism of action lies in the selective inhibition of xanthine oxidase (XO), thereby blocking the uric acid formation step in the purine metabolism pathway. Unlike drugs that simply promote uric acid excretion,...0 Commenti 0 condivisioni 937 Views 0 Anteprima
-
Eplerenone: A Highly Selective Mineralocorticoid Receptor Antagonist for Cardiovascular ProtectionWhat Is Eplerenone? Eplerenone is a highly selective aldosterone receptor antagonist (MRA) with a well-defined and stable clinical position in the treatment of cardiovascular diseases. From a chemical biology perspective, eplerenone selectively binds to mineralocorticoid receptors (MRs) with high affinity, blocking aldosterone-mediated gene transcriptional regulation, thereby inhibiting sodium...0 Commenti 0 condivisioni 1K Views 0 Anteprima
-
Gefitinib: A Selective EGFR Tyrosine Kinase Inhibitor for Targeted Lung Cancer TherapyWhat Is Gefitinib? Gefitinib is a small molecule, highly selective EGFR tyrosine kinase inhibitor (EGFR-TKI). It is primarily used for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations. Gefitinib functions as an EGFR inhibitor by selectively binding to the ATP-binding site of the EGFR tyrosine kinase domain. This binding prevents the autophosphorylation of...0 Commenti 0 condivisioni 1K Views 0 Anteprima